Friday 1 August 2014

Malaria Vaccine Marketed Soon Newest

The active ingredient bitter, andrographolide, proved effective in inhibiting the growth of the malaria parasite and has potential as an anti-malarial drug

Liputan6.com, Jakarta British drug company, GlaxoSmithKline (GSK) last week asking for approval to the European Medicines Agency (European Medicines Agency) in order to market a malaria vaccine called RTS, S.

The submission is based on the ability of GSK-made vaccine is able to protect the little baby for 18 months and managed through the most vulnerable time, researchers said as quoted by page of NBC News, Wednesday (07/30/2014).

After testing this vaccine to more than 15,000 babies aged 6 weeks to 17 months showed almost half of them, or about 46% protected from malaria for 18 months. The vaccine is given in a three dose series as revealed Mary Hamel of US Centers for Disease Control and Prevention.

Other evidence, the vaccine successfully protected 800 of the 1,000 children for this disease inevitable as reported PLoS Medicine.

To note, malarian is one of the major diseases in dunia.WHO estimates that about 200 million cases of malaria per year and kills 600,000 people, mostly children.